I know the shareholders werent happy but you also have to realize that WP also lost money on that deal. They will be in the same position with Talon. Both drugs are not blockbusters and the sales of Folotyn were pretty bad which was reflected in the stock price. Investor did have a chance to get out with good profits after approval. Hopefully we will have the same chance that Allos investors had.